The Ponce de Leon Center CRS

Location	341 Ponce de Leon Avenue, N.E. Atlanta, GA 30308-2012 United States of America http://poncecrs.emory.edu/
Phone	404-616-6313
CRS Coordinator	Ericka Patrick erpatri@emory.edu 404-616-6313
CRS Leader	Carlos del Rio cdelrio@emory.edu 404-727-1557
Studies	A5128: US Genomic Sampling A5322: Long-Term Follow-up of Older HIV-infected Adults in the ACTG: Addressing Issues of Aging, HIV Infection and Inflammation (HAILO) A5324: A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV A5332: REPRIEVE Trial A5354: Early ART in Acute HIV A5357: A Study of Long-Acting Cabotegravir Plus VRC01LS to Maintain Viral Suppression in HIV-1-Infected Adults A5359: The LATITUDE Study A5360: MINMON Study-Monitoring SOF/VEL in Treatment Naïve, Chronic HCV Participants A5361s: Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE) A5366: Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation with Histone Deacetylase Inhibitors A5368:Anti-PD-1 Antibody in HBV Infected on Suppressive Antiviral Therapy A5370: Anti-PD-1 Antibody in HIV-1 A5377: Tri-specific Antibody A5380: Glecaprevir/pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C) A5395: A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons with COVID-19 A5372: Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals (RPT-DTG PK Study) A5401: ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies